This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Natural killer cell-based immunotherapy for acute myeloid leukemia
Journal of Hematology & Oncology Open Access 07 December 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27: 1229–1235.
Andreola G, Labopin M, Beelen D, Chevallier P, Tabrizi R, Bosi A et al. Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years. Bone Marrow Transplant 2015; 50: 1508–1512.
Stölzel F, Hackmann K, Kuithan F, Mohr B, Füssel M, Oelschlägel U et al. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation 2012; 93: 744–749.
Salama AK, Hodi FS . Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2011; 17: 4622–4628.
Pistillo MP . CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003; 101: 202–209.
Laurent S, Palmisano GL, Martelli AM, Kato T, Tazzari PL, Pierri I et al. CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis. Br J Haematol 2007; 136: 597–608.
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016; 375: 143–153.
Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1581–1588.
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.
Krauter J, Wagner K, Schafer I, Marschalek R, Meyer C, Heil G et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2009; 27: 3000–3006.
Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L, Socié G et al. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia 2015; 29: 2375–2381.
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.
Singh AK, Porrata LF, Aljitawi O, Lin T, Shune L, Ganguly S et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma. Bone Marrow Transplant 2016; 51: 1268–1270.
Mori S, Ahmed W, Patel R, Dohrer A . Steroid refractory acute liver GVHD in a Hodgkin’s patient after allogeneic stem transplant cell transplantation following treatment with Anti PD-1 antibody, nivolumab, for relapsed disease. Biol Blood Marrow Transplant 2016; 22: S392.
Herbaux C, Gauthier J, Brice P, Fornecker L, Bouabdallah K, Manson G et al. Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin’s lymphoma after allogeneic hematopoietic cell transplantation: a Study from the Lysa and SFGM-TC. Blood 2015; 126: 3979.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Gros, FX., Cazaubiel, T., Forcade, E. et al. Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation. Bone Marrow Transplant 52, 1047–1048 (2017). https://doi.org/10.1038/bmt.2017.78
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.78
This article is cited by
-
Natural killer cell-based immunotherapy for acute myeloid leukemia
Journal of Hematology & Oncology (2020)
-
Ipilimumab
Reactions Weekly (2017)